$1.5799
-0.0001[-0.01%]
At close: Apr 23
$1.5799
0[0.00%]
After Hours: 6:26PM EDT
Inhibikase Therapeutics
(NASDAQ:IKT)Inhibikase Therapeutics Stock (NASDAQ:IKT), Quotes and News Summary
Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.
| Open | $1.630 |
| Close | $1.870 |
| Volume / Avg. | 62.108K / 140.512K |
| Day Range | 1.543 - 1.870 |
| 52 Wk Range | 0.790 - 4.351 |
| Market Cap | $10.233M |
| P/E Ratio | - |
| Dividend Yield | - |
| Exchange | NASDAQ |
| RSI | 43 |
| Short Interest | 0.36% |
| Days to Cover | 1 |
Recent News
Financials
Quarterly
Annual
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
About Inhibikase Therapeutics Inc
Sector
Health Care
Industry
Biotechnology
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase i...
Show More
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Inhibikase Therapeutics (IKT) stock?
You can purchase shares of Inhibikase Therapeutics (NASDAQ: IKT) through any online brokerage.
Who are Inhibikase Therapeutics's (IKT) competitors?
Other companies in Inhibikase Therapeutics’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Virios Therapeutics (NASDAQ:VIRI), Imunon (NASDAQ:IMNN), Monopar Therapeutics (NASDAQ:MNPR) and Coeptis Therapeutics (NASDAQ:COEP).
What is the target price for Inhibikase Therapeutics (IKT) stock?
The latest price target for Inhibikase Therapeutics (NASDAQ: IKT) was reported by HC Wainwright & Co. on Thursday, March 7, 2024. The analyst firm set a price target for 27.00 expecting IKT to rise to within 12 months (a possible 1608.97% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for Inhibikase Therapeutics (IKT)?
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $1.5799 last updated April 23, 2024 at 6:26 PM EDT.
Does Inhibikase Therapeutics (IKT) pay a dividend?
There are no upcoming dividends for Inhibikase Therapeutics.
When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?
Inhibikase Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
Is Inhibikase Therapeutics (IKT) going to split?
There is no upcoming split for Inhibikase Therapeutics.
What sector and industry does Inhibikase Therapeutics (IKT) operate in?
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.